Press Releases

06.11.2020

FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)

06.10.2020

Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis

06.03.2020

Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology

06.02.2020

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

05.29.2020

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

05.29.2020

Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer

05.22.2020

Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC

05.18.2020

Pfizer Prices $4,000,000,000 Debt Offering

05.15.2020

Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study

05.14.2020

Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

05.13.2020

Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day

05.12.2020

New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program